Crikker, My point in using ABBV was not to compare it to AMRN today...but to what AMRN may eventually become in a GIA scenario perhaps 5 or 6 years from now. ABBV has substantial debt...AMRN has none. (Not counting the royalty thingy.)
A GIA will require diversification by AMRN...perhaps acquiring companies such as VKTX and AVXL. Such acquisitions will require dilution or debt for those companies as well as money for further testing of new medications.
In a GIA scenario, the sales force would likely be expanded further and that may reduce profit margins. You are correct that ABBV today is a value stock. In 5 or 6 years from now AMRN may be seen as a value stock.
In any case John Thero has had many years to formulate his game plan for AMRN. It will be interesting to watch it unfold and hopefully rewarding for the long-term investors here.